Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Guggenheim analyst Delma Caiati has initiated coverage on Ovid Therapeutics (NASDAQ: OVID) with a Buy rating. The firm has set a price target of $7 for the company's stock.